Cost-effectiveness analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at low risk of surgical mortality in Sweden
TAVI with SAPIEN 3 is a cost-effective option versus SAVR for patients with symptomatic severe aortic stenosis at low risk for surgical mortality treated in the Swedish healthcare setting. These findings may inform policy decisions in Sweden for the management of this patient group.
Authors
- Niels Erik Nielsen (ORCID: https://orcid.org/0000-0003-3633-0549)
- Matthias Götberg (ORCID: https://orcid.org/0000-0002-0912-7927)
- Konrad Nilsson (ORCID: https://orcid.org/0000-0002-8329-5072)
- Henrik Hagström
- Henrik Bjursten (ORCID: https://orcid.org/0000-0001-5428-7455)
- Tom Bromilow (ORCID: https://orcid.org/0000-0003-2494-5685)
- Archita Sarmah (ORCID: https://orcid.org/0000-0003-3857-3894)
- Chiara Malmberg
- Pascal Candolfi (ORCID: https://orcid.org/0000-0001-6728-451X)
- Magnus Settergren (ORCID: https://orcid.org/0000-0001-7731-6730)
- Stefan James
- Oskar Angerås (ORCID: https://orcid.org/0000-0002-3474-2438)
- Jenny Backes (ORCID: https://orcid.org/0009-0008-3439-178X)
Institutions
- Uppsala University (SE)
- Karolinska University Hospital (SE)
- Lund University (SE)
- Sahlgrenska University Hospital (SE)
- Leeds and York Partnership NHS Foundation Trust (GB)
- Karolinska Institutet (SE)
- Swedish Institute for Health Economics (SE)
- Örebro University Hospital (SE)
- Skåne University Hospital (SE)
- Linköping University Hospital (SE)
- University of York (GB)
- University of Gothenburg (SE)
- Umeå University (SE)
- Edwards Lifesciences (Switzerland) (CH)
Publication Details
- Journal
- Upsala Journal of Medical Sciences
- Published
- 2024-11-11
- DOI
- https://doi.org/10.48101/ujms.v129.10741
- Citations
- 2
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Edwards Lifesciences